Strides Pharma Gains as Subsidiary Partners with Kenox for Nasal Spray Development

Mumbai, September 9 (Kiran News) — Shares of Strides Pharma Science edged higher on Tuesday after its step-down wholly owned subsidiary, Strides Pharma Global (Singapore), entered into a strategic product development partnership with Kenox Pharmaceuticals Inc.

Strides Pharma Science

Kenox, a fast-growing contract development and manufacturing company, specializes in Orally Inhaled and Nasal Drug Products (OINDPs). Under the partnership, Strides and Kenox will jointly develop and file multiple nasal spray products for the US market, covering diverse therapeutic indications.

The collaboration aims to build a pipeline of nasal spray products, leveraging Strides’ commercial presence in the US and Kenox’s expertise in OINDPs to deliver affordable, high-quality therapies.

On the BSE, Strides Pharma Science was trading at ₹885.10, up by ₹4.05 or 0.46 percent from its previous close of ₹881.05. The stock opened at ₹896.95 and touched an intraday high of ₹897.00 and a low of ₹885.00. A total of 1,742 shares were traded during the session.

The Group ‘A’ stock, with a face value of ₹10, has a 52-week high of ₹971.90 (July 29, 2025) and a 52-week low of ₹530.70 (January 27, 2025). Over the past week, it traded between ₹878.00 and ₹913.80.

The company’s market capitalization currently stands at ₹8,195.54 crore. Promoters hold 28.30 percent stake, institutions own 41.33 percent, while non-institutional investors account for 30.37 percent.

Strides Pharma Science, formerly known as Strides Shasun, is focused on the development and manufacture of IP-led niche finished dosage formulations and is among the world’s largest producers of soft gelatin capsules.

BREAKING NEWS:
Sara Shines in Royal Look at Brother’s Mehndi Ceremony “UTS App shutting down March 1; switch to Railone!” Realme C83 5G launching in India on March 7!